The estimated Net Worth of John Patrick Jr Shannon is at least $5.3 Milione dollars as of 17 November 2023. Mr. Shannon owns over 30,769 units of Xeris Biopharma Inc stock worth over $4,028,525 and over the last 6 years he sold XERS stock worth over $0. In addition, he makes $1,267,580 as President e Chief Operating Officer at Xeris Biopharma Inc.
Sign up
Mr. Shannon XERS stock SEC Form 4 insiders trading
John has made over 5 trades of the Xeris Biopharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 30,769 units of XERS stock worth $50,461 on 17 November 2023.
The largest trade he's ever made was buying 100,000 units of Xeris Biopharma Inc stock on 11 November 2021 worth over $210,000. On average, John trades about 9,595 units every 76 days since 2018. As of 17 November 2023 he still owns at least 1,408,575 units of Xeris Biopharma Inc stock.
You can see the complete history of Mr. Shannon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Shannon biography
John P. Shannon serves as President, Chief Operating Officer of the Company. Mr. Shannon joined the Company in February 2017 as its Chief Operating Officer. Previously, from 2015 until its acquisition in 2016, Mr. Shannon served as chief executive officer and director for Catheter Connections, Inc. Prior to that, from 2012 until its acquisition in 2014, Mr. Shannon served as chief commercial officer for Durata Therapeutics, a biopharmaceutical company. From 2002 to 2012, he held several roles at Baxter Healthcare, including Vice President and General Manager of U.S. BioScience and General Manager, Global Hemophilia and Global Commercial Excellence. Mr. Shannon received a B.S. degree in biology with an emphasis in microbiology from Western Illinois University.
What is the salary of John Shannon?
As the President e Chief Operating Officer of Xeris Biopharma Inc, the total compensation of John Shannon at Xeris Biopharma Inc is $1,267,580. There are 1 executives at Xeris Biopharma Inc getting paid more, with Paul Edick having the highest compensation of $4,307,640.
How old is John Shannon?
John Shannon is 58, he's been the President e Chief Operating Officer of Xeris Biopharma Inc since 2020. There are 7 older and 11 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.
What's John Shannon's mailing address?
John's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.
Insiders trading at Xeris Biopharma Inc
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... e Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
What does Xeris Biopharma Inc do?
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
What does Xeris Biopharma Inc's logo look like?
Complete history of Mr. Shannon stock trades at Xeris Biopharma Inc
Xeris Biopharma Inc executives and stock owners
Xeris Biopharma Inc executives and other stock owners filed with the SEC include:
-
Paul Edick,
Chairman of the Board, Chief Executive Officer -
John Shannon,
President, Chief Operating Officer -
Paul R. Edick,
Chairman & CEO -
Barry Deutsch,
Chief Financial Officer -
John P. Shannon,
Pres, COO & Director -
Beth Hecht,
Senior Vice President, General Counsel, Corporate Secretary -
Beth P. Hecht J.D.,
Sr. VP, Gen. Counsel, Corp. Sec. & Director -
John Schmid,
Lead Independent Director -
BJ Bormann,
Independent Director -
Marla Persky,
Independent Director -
Jeffrey Sherman,
Independent Director -
Dawn Halkuff,
Independent Director -
Mark Thierer,
Independent Director -
Kenneth Johnson,
Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs -
Steven Prestrelski,
Co-Founder, Chief Scientific Officer -
Dr. Steven J. Prestrelski MBA, Ph.D.,
Co-Founder & Chief Scientific Officer -
Kevin McCulloch,
Sr. VP of Global Operations & Bus. Devel. -
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs -
Barry M. Deutsch,
Exec. Officer -
Allison Wey,
Sr. VP of Investor Relations & Corp. Communications -
Steven M. Pieper,
Chief Financial Officer -
Dr. Steven J. Prestrelski,
Co-Founder & Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt L.P....,
-
Partners, Ltd.Palmetto Part...,
-
Barbara Jean Anne Bormann K...,
Director -
Jonathan Rigby,
Director -
Kevin Mc Culloch,
See Remarks -
Steven Pieper,
See Remarks -
John Johnson,
Director -
Garheng Kong,
Director -
Ricki Louise Fairley,
Director